Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

Int J Rheum Dis. 2015 May;18(4):473-5. doi: 10.1111/1756-185X.12521. Epub 2014 Dec 18.

Authors

Luca Cantarini¹, Giuseppe Lopalco², Antonio Vitale¹, Francesco Caso^{1

3}, Giovanni Lapadula², Florenzo Iannone², Mauro Galeazzi¹, Donato Rigante⁴

Affiliations

¹ Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Policlinico "Le Scotte", University of Siena, Siena, Italy.
² Interdisciplinary Department of Medicine, Rheumatology Unit, Policlinic Hospital, University of Bari, Bari, Italy.
³ Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy.
⁴ Institute of Pediatrics, Università Cattolica Sacro Cuore, Rome, Italy.

PMID: 25522898
DOI: 10.1111/1756-185X.12521

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Drug Administration Schedule
Fever / drug therapy*
Fever / genetics*
Follow-Up Studies
Genetic Variation
Hereditary Autoinflammatory Diseases / drug therapy*
Hereditary Autoinflammatory Diseases / genetics*
Humans
Injections, Subcutaneous
Male
Mutation
Penetrance*
Receptors, Tumor Necrosis Factor, Type I / drug effects*
Receptors, Tumor Necrosis Factor, Type I / genetics
Risk Assessment
Severity of Illness Index
Treatment Failure

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Receptors, Tumor Necrosis Factor, Type I
TNFRSF1A protein, human
canakinumab

Supplementary concepts

Periodic fever, familial, autosomal dominant